Nyxoah

Company Overview

Snapshot

Founded in January 2008 by Robert Taub, Nyxoah operates with 51–200 employees. The company has raised a total of $270.7 million across 10 funding rounds from 9 investors. In October 2024, Nyxoah secured $27 million through an At-the-Market Offering.

Business overview

Nyxoah is a medical device company specializing in the development and commercialization of hypoglossal nerve stimulation therapy for obstructive sleep apnea (OSA). The company's core product is a battery-free, leadless, minimally invasive neurostimulator designed for patients with moderate to severe OSA who have not responded to conventional positive airway pressure therapy. Nyxoah serves the healthcare and life sciences sectors, focusing on medical devices, medical treatment, and therapeutics for chronic patients.

Strategic signal

In October 2024, Nyxoah raised $27 million through an At-the-Market Offering. This capital infusion is a significant validation of investor confidence in the company's strategic growth and ongoing preparations for expanding its presence, particularly in the U.S. market, as highlighted by its Q2 2024 earnings call. This financial move signals a strengthened position for Nyxoah to advance its innovative sleep apnea device and market penetration efforts.

Company Intelligence Q&A

What is Nyxoah's primary focus?

Nyxoah focuses on the development and commercialization of hypoglossal nerve stimulation therapy for the treatment of obstructive sleep apnea (OSA).

When did Nyxoah go public on Euronext?

Nyxoah launched its Initial Public Offering on Euronext Brussels in September 2020.

What was a key financial event for Nyxoah in October 2024?

In October 2024, Nyxoah secured $27 million through an At-the-Market Offering, as reported by GlobeNewswire, to boost its U.S. presence.

When did Nyxoah receive CE marking for its therapy?

In March 2019, Nyxoah received CE marking for its novel hypoglossal nerve stimulation therapy for the treatment of obstructive sleep apnea.

What was a significant partnership announced in September 2023?

In September 2023, Nyxoah announced a partnership with ResMed in Germany, as reported by Yahoo Finance, to expand the commercialization of its Genio system.